• In recent days, Eli Lilly announced multiple R&D agreements, including global rights to AlzeCure’s preclinical Alzheimer’s candidate ACD680 with potential milestones above US$1.00 billion, an ion channel collaboration with OmniAb, and a taRNA vaccine partnership with Amplitude Therapeutics, while also securing UK approval of its once-daily oral GLP‑1 drug Foundayo for weight management and type 2 diabetes.
• These deals and the Foundayo approval deepen Lilly’s presence in obesity, neuroscience, and infectious disease therapies, reinforcing its emphasis on high‑value innovation and pipeline breadth.
• We’ll now examine how the UK approval of Foundayo reshapes Eli Lilly’s investment narrative, particularly its GLP‑1 leadership and growth drivers.

AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Eli Lilly Investment Narrative Recap

To own Eli Lilly, you have to believe its GLP‑1 franchise can keep driving the business while management broadens beyond a few blockbuster obesity and diabetes drugs. The UK approval of oral GLP‑1 Foundayo looks supportive for near term growth drivers, but it does not remove key risks around pricing pressure, payer access, and heavy dependence on incretin therapies.

Among the recent announcements, the UK green light for Foundayo stands out as most relevant. It adds a once daily oral option to Lilly’s already strong injectable GLP‑1 lineup, strengthening its leadership in obesity and type 2 diabetes just as competitors push into oral treatments. Foundayo’s rollout now becomes a central catalyst to watch against the backdrop of reimbursement debates and potential formulary exclusions.

Yet, even as Foundayo expands Lilly’s reach, investors should be aware that payer pushback and reimbursement limits could still...

Eli Lilly's narrative projects $118.0 billion revenue and $48.7 billion earnings by 2029. This requires 14.0% yearly revenue growth and about a $22.0 billion earnings increase from $26.7 billion today.

Uncover how Eli Lilly's forecasts yield a $1297 fair value, in line with its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling revenue near US$124.5 billion and earnings of US$50.0 billion by 2029, so if you buy into that upside, this latest Foundayo approval could either support those ambitious views or expose how dependent they are on aggressive assumptions about GLP 1 adoption and pricing power.

Explore 12 other fair value estimates on Eli Lilly - why the stock might be worth 7% less than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Eli Lilly research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Eli Lilly research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Eli Lilly's overall financial health at a glance.

No Opportunity In Eli Lilly?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Outshine the giants: these 17 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.